SignalFDA/Bio

Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials

6% jump driven by Phase 3 trial success for MS drug.

What changed

Why it matters

6% jump driven by Phase 3 trial success for MS drug.

Sources